Business
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
PALO ALTO, Calif., Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and
About this update from Kodiak Sciences Inc
[{"type":"text","content":"PALO ALTO, Calif., Oct. 11, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that three scientific presentations on tarcocimab tedromer (KSI-301), including a first-time presentation of the primary results from the Phase 3 DAYLIGHT study in wet age-related macular degeneration (AMD), a first-time presentation of the Year 1 head-to-head results from the Phase 3 BEACON study in retinal vein occlusion (RVO), and the primary results and new analyses from the Phase 3 GLEAM and GLIMMER studies in diabetic macular edema (DME), will be shared at the 56th Annual Scientific Meeting of The Retina Society, being held from Oct 11 – 14 in New York, United States.\n\n\"At the Retina Society meeting, data will be presented across four pivotal trials for tarcocimab and will include the results of recent investigations on the higher cataract incidence in patients with DME and the implications of our ongoing findings on the development of our ABC Platform derived medicines,\" said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.\nThe following will be presented at the meeting by our clinical investigators:\nTitle: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of wAMD: One-year primary efficacy,durability, and safety outcomes of the Phase 3 DAYLIGHT StudyPresentation Date and Time: October 13, 2023; 8:52 AM ETPresenter: Brandon Busbee, M.D., Tennessee Retina and Retina Consultants of America\nTitle: Tarcocimab tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for Diabetic Macular Edema: Primary Endpoint Efficacy and Safety Outcomes of the GLEAM and GLIMMER Phase 3 Pivotal StudiesPresentation Date and Time: October 13, 2023; 10:28 AM ETPresenter: Robert Wong, M.D., FASRS, Austin Retina Associates\nTitle: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of RVO: One-year primary efficacy, durability, and safety outcomes of the Phase 3 BEACON StudyPresentation Date and Time: October 13, 2023; 10:38 AM ETPresenter: Ankoor Shah, M.D., Retina Consultants of Texas\nKodiak plans to post the presentation slides on the \"Events and Presentations\" section of Kodiak's website at http://ir.kodiak.com/ at the beginning of each presentation.\nAbout ...